ID   NMRL1_HUMAN             Reviewed;         299 AA.
AC   Q9HBL8;
DT   20-FEB-2007, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2001, sequence version 1.
DT   28-JUN-2023, entry version 157.
DE   RecName: Full=NmrA-like family domain-containing protein 1;
GN   Name=NMRAL1; Synonyms=HSCARG;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Adrenal gland;
RA   Xiao H., Song H., Gao G., Ren S., Chen Z., Han Z.;
RL   Submitted (JAN-2000) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15616553; DOI=10.1038/nature03187;
RA   Martin J., Han C., Gordon L.A., Terry A., Prabhakar S., She X., Xie G.,
RA   Hellsten U., Chan Y.M., Altherr M., Couronne O., Aerts A., Bajorek E.,
RA   Black S., Blumer H., Branscomb E., Brown N.C., Bruno W.J., Buckingham J.M.,
RA   Callen D.F., Campbell C.S., Campbell M.L., Campbell E.W., Caoile C.,
RA   Challacombe J.F., Chasteen L.A., Chertkov O., Chi H.C., Christensen M.,
RA   Clark L.M., Cohn J.D., Denys M., Detter J.C., Dickson M.,
RA   Dimitrijevic-Bussod M., Escobar J., Fawcett J.J., Flowers D., Fotopulos D.,
RA   Glavina T., Gomez M., Gonzales E., Goodstein D., Goodwin L.A., Grady D.L.,
RA   Grigoriev I., Groza M., Hammon N., Hawkins T., Haydu L., Hildebrand C.E.,
RA   Huang W., Israni S., Jett J., Jewett P.B., Kadner K., Kimball H.,
RA   Kobayashi A., Krawczyk M.-C., Leyba T., Longmire J.L., Lopez F., Lou Y.,
RA   Lowry S., Ludeman T., Manohar C.F., Mark G.A., McMurray K.L., Meincke L.J.,
RA   Morgan J., Moyzis R.K., Mundt M.O., Munk A.C., Nandkeshwar R.D.,
RA   Pitluck S., Pollard M., Predki P., Parson-Quintana B., Ramirez L., Rash S.,
RA   Retterer J., Ricke D.O., Robinson D.L., Rodriguez A., Salamov A.,
RA   Saunders E.H., Scott D., Shough T., Stallings R.L., Stalvey M.,
RA   Sutherland R.D., Tapia R., Tesmer J.G., Thayer N., Thompson L.S., Tice H.,
RA   Torney D.C., Tran-Gyamfi M., Tsai M., Ulanovsky L.E., Ustaszewska A.,
RA   Vo N., White P.S., Williams A.L., Wills P.L., Wu J.-R., Wu K., Yang J.,
RA   DeJong P., Bruce D., Doggett N.A., Deaven L., Schmutz J., Grimwood J.,
RA   Richardson P., Rokhsar D.S., Eichler E.E., Gilna P., Lucas S.M.,
RA   Myers R.M., Rubin E.M., Pennacchio L.A.;
RT   "The sequence and analysis of duplication-rich human chromosome 16.";
RL   Nature 432:988-994(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Skin, and Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   FUNCTION, INTERACTION WITH ASS1, SUBCELLULAR LOCATION, INDUCTION, AND
RP   REGION.
RX   PubMed=18263583; DOI=10.1074/jbc.m708697200;
RA   Zhao Y., Zhang J., Li H., Li Y., Ren J., Luo M., Zheng X.;
RT   "An NADPH sensor protein (HSCARG) down-regulates nitric oxide synthesis by
RT   association with argininosuccinate synthetase and is essential for
RT   epithelial cell viability.";
RL   J. Biol. Chem. 283:11004-11013(2008).
RN   [5]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [6]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) IN COMPLEX WITH NADP, FUNCTION,
RP   HOMODIMERIZATION, INTERACTION WITH ASS1, AND SUBCELLULAR LOCATION.
RX   PubMed=17496144; DOI=10.1073/pnas.0700480104;
RA   Zheng X., Dai X., Zhao Y., Chen Q., Lu F., Yao D., Yu Q., Liu X., Zhang C.,
RA   Gu X., Luo M.;
RT   "Restructuring of the dinucleotide-binding fold in an NADP(H) sensor
RT   protein.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:8809-8814(2007).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF MUTANT ALA-37, X-RAY
RP   CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF MUTANT ALA-81, FUNCTION, SUBUNIT,
RP   SUBCELLULAR LOCATION, AND MUTAGENESIS OF ARG-37; LYS-41; TYR-81 AND
RP   LYS-133.
RX   PubMed=19254724; DOI=10.1016/j.jmb.2009.02.049;
RA   Dai X., Li Y., Meng G., Yao S., Zhao Y., Yu Q., Zhang J., Luo M., Zheng X.;
RT   "NADPH is an allosteric regulator of HSCARG.";
RL   J. Mol. Biol. 387:1277-1285(2009).
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) IN COMPLEX WITH NIFLUMIC ACID.
RG   Structural genomics consortium (SGC);
RT   "Crystal structure of NMRA-like family domain containing protein 1 in
RT   complex with niflumic acid.";
RL   Submitted (AUG-2009) to the PDB data bank.
CC   -!- FUNCTION: Redox sensor protein. Undergoes restructuring and subcellular
CC       redistribution in response to changes in intracellular NADPH/NADP(+)
CC       levels. At low NADPH concentrations the protein is found mainly as a
CC       monomer, and binds argininosuccinate synthase (ASS1), the enzyme
CC       involved in nitric oxide synthesis. Association with ASS1 impairs its
CC       activity and reduces the production of nitric oxide, which subsecuently
CC       prevents apoptosis. Under normal NADPH concentrations, the protein is
CC       found as a dimer and hides the binding site for ASS1. The homodimer
CC       binds one molecule of NADPH. Has higher affinity for NADPH than for
CC       NADP(+). Binding to NADPH is necessary to form a stable dimer.
CC       {ECO:0000269|PubMed:17496144, ECO:0000269|PubMed:18263583,
CC       ECO:0000269|PubMed:19254724}.
CC   -!- SUBUNIT: Homodimer. Interacts with ASS1. Interaction is enhanced by low
CC       NADPH/NADP(+) ratios, which results in inhibition of ASS1 activity.
CC       {ECO:0000269|PubMed:17496144, ECO:0000269|PubMed:18263583,
CC       ECO:0000269|PubMed:19254724, ECO:0000269|Ref.8}.
CC   -!- INTERACTION:
CC       Q9HBL8; P00966: ASS1; NbExp=3; IntAct=EBI-2862643, EBI-536842;
CC       Q9HBL8; Q9HBL8: NMRAL1; NbExp=2; IntAct=EBI-2862643, EBI-2862643;
CC       Q9HBL8; Q96CV9: OPTN; NbExp=3; IntAct=EBI-2862643, EBI-748974;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Cytoplasm, perinuclear region.
CC       Nucleus. Note=Under normal redox growth conditions localizes in the
CC       cytoplasm and perinuclear region. Nuclear localization is promoted by
CC       increased intracellular nitric oxide and reduced NADPH/NADP(+) ratios.
CC   -!- INDUCTION: By nitric oxide, cGMP and pro-inflammatory cytokines.
CC       {ECO:0000269|PubMed:18263583}.
CC   -!- MISCELLANEOUS: Reduced levels of NMRAL1 by RNAi increases nitric oxide
CC       production and reduces cell viability. Overexpression of NMRAL1
CC       increases cell viability.
CC   -!- SIMILARITY: Belongs to the NmrA-type oxidoreductase family.
CC       {ECO:0000305}.
CC   -!- CAUTION: Lacks the conserved Tyr residue in the active site triad of
CC       Ser-Tyr-Lys necessary for dehydrogenase activity, suggesting that it
CC       has no oxidoreductase activity. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF225419; AAG09721.1; -; mRNA.
DR   EMBL; AC012676; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC007606; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC002927; AAH02927.1; -; mRNA.
DR   EMBL; BC007364; AAH07364.1; -; mRNA.
DR   CCDS; CCDS10516.1; -.
DR   RefSeq; NP_001292070.1; NM_001305141.1.
DR   RefSeq; NP_001292071.1; NM_001305142.1.
DR   RefSeq; NP_065728.1; NM_020677.4.
DR   PDB; 2EXX; X-ray; 2.40 A; A/B=1-299.
DR   PDB; 2WM3; X-ray; 1.85 A; A=1-298.
DR   PDB; 2WMD; X-ray; 2.00 A; A=1-298.
DR   PDB; 3DXF; X-ray; 2.20 A; A/B=1-299.
DR   PDB; 3E5M; X-ray; 2.70 A; A/B=1-299.
DR   PDBsum; 2EXX; -.
DR   PDBsum; 2WM3; -.
DR   PDBsum; 2WMD; -.
DR   PDBsum; 3DXF; -.
DR   PDBsum; 3E5M; -.
DR   AlphaFoldDB; Q9HBL8; -.
DR   SMR; Q9HBL8; -.
DR   BioGRID; 121509; 245.
DR   DIP; DIP-60944N; -.
DR   IntAct; Q9HBL8; 6.
DR   STRING; 9606.ENSP00000458762; -.
DR   BindingDB; Q9HBL8; -.
DR   ChEMBL; CHEMBL4802017; -.
DR   DrugBank; DB08784; 2-(4-CHLORO-PHENYLAMINO)-NICOTINIC ACID.
DR   GlyGen; Q9HBL8; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q9HBL8; -.
DR   PhosphoSitePlus; Q9HBL8; -.
DR   SwissPalm; Q9HBL8; -.
DR   BioMuta; NMRAL1; -.
DR   DMDM; 74734255; -.
DR   CPTAC; CPTAC-1624; -.
DR   EPD; Q9HBL8; -.
DR   jPOST; Q9HBL8; -.
DR   MassIVE; Q9HBL8; -.
DR   MaxQB; Q9HBL8; -.
DR   PaxDb; Q9HBL8; -.
DR   PeptideAtlas; Q9HBL8; -.
DR   ProteomicsDB; 81572; -.
DR   Antibodypedia; 24328; 127 antibodies from 26 providers.
DR   DNASU; 57407; -.
DR   Ensembl; ENST00000283429.11; ENSP00000283429.6; ENSG00000153406.14.
DR   Ensembl; ENST00000404295.7; ENSP00000383962.3; ENSG00000153406.14.
DR   Ensembl; ENST00000574425.5; ENSP00000460263.1; ENSG00000153406.14.
DR   Ensembl; ENST00000574733.5; ENSP00000458762.1; ENSG00000153406.14.
DR   Ensembl; ENST00000616587.2; ENSP00000479569.1; ENSG00000274684.4.
DR   Ensembl; ENST00000621810.4; ENSP00000478990.1; ENSG00000274684.4.
DR   Ensembl; ENST00000632013.1; ENSP00000488692.1; ENSG00000274684.4.
DR   Ensembl; ENST00000633085.1; ENSP00000488644.1; ENSG00000274684.4.
DR   GeneID; 57407; -.
DR   KEGG; hsa:57407; -.
DR   MANE-Select; ENST00000283429.11; ENSP00000283429.6; NM_020677.6; NP_065728.1.
DR   UCSC; uc002cwm.4; human.
DR   AGR; HGNC:24987; -.
DR   CTD; 57407; -.
DR   DisGeNET; 57407; -.
DR   GeneCards; NMRAL1; -.
DR   HGNC; HGNC:24987; NMRAL1.
DR   HPA; ENSG00000153406; Low tissue specificity.
DR   MIM; 620004; gene.
DR   neXtProt; NX_Q9HBL8; -.
DR   OpenTargets; ENSG00000153406; -.
DR   PharmGKB; PA145007922; -.
DR   VEuPathDB; HostDB:ENSG00000153406; -.
DR   eggNOG; ENOG502RG69; Eukaryota.
DR   GeneTree; ENSGT00940000160872; -.
DR   InParanoid; Q9HBL8; -.
DR   OMA; FMENTVA; -.
DR   OrthoDB; 5386438at2759; -.
DR   PhylomeDB; Q9HBL8; -.
DR   TreeFam; TF335532; -.
DR   BioCyc; MetaCyc:ENSG00000153406-MON; -.
DR   PathwayCommons; Q9HBL8; -.
DR   Reactome; R-HSA-70635; Urea cycle.
DR   SignaLink; Q9HBL8; -.
DR   BioGRID-ORCS; 57407; 17 hits in 1076 CRISPR screens.
DR   ChiTaRS; NMRAL1; human.
DR   EvolutionaryTrace; Q9HBL8; -.
DR   GenomeRNAi; 57407; -.
DR   Pharos; Q9HBL8; Tbio.
DR   PRO; PR:Q9HBL8; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   RNAct; Q9HBL8; protein.
DR   Bgee; ENSG00000153406; Expressed in granulocyte and 94 other tissues.
DR   ExpressionAtlas; Q9HBL8; baseline and differential.
DR   Genevisible; Q9HBL8; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   CDD; cd08947; NmrA_TMR_like_SDR_a; 1.
DR   Gene3D; 3.40.50.720; NAD(P)-binding Rossmann-like Domain; 1.
DR   Gene3D; 3.90.25.10; UDP-galactose 4-epimerase, domain 1; 1.
DR   InterPro; IPR036291; NAD(P)-bd_dom_sf.
DR   InterPro; IPR008030; NmrA-like.
DR   PANTHER; PTHR42748; NITROGEN METABOLITE REPRESSION PROTEIN NMRA FAMILY MEMBER; 1.
DR   PANTHER; PTHR42748:SF16; NMRA-LIKE FAMILY DOMAIN-CONTAINING PROTEIN 1; 1.
DR   Pfam; PF05368; NmrA; 1.
DR   SUPFAM; SSF51735; NAD(P)-binding Rossmann-fold domains; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cytoplasm; NADP; Nucleus; Reference proteome.
FT   CHAIN           1..299
FT                   /note="NmrA-like family domain-containing protein 1"
FT                   /id="PRO_0000278204"
FT   REGION          153..189
FT                   /note="Interaction with ASS1"
FT   BINDING         11..16
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /ligand_note="ligand shared between dimeric partners"
FT                   /note="in other chain"
FT                   /evidence="ECO:0000269|PubMed:17496144"
FT   BINDING         37..41
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /ligand_note="ligand shared between dimeric partners"
FT                   /note="in other chain"
FT                   /evidence="ECO:0000269|PubMed:17496144"
FT   BINDING         58..59
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /ligand_note="ligand shared between dimeric partners"
FT                   /note="in other chain"
FT                   /evidence="ECO:0000269|PubMed:17496144"
FT   BINDING         62
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /ligand_note="ligand shared between dimeric partners"
FT                   /evidence="ECO:0000269|PubMed:17496144"
FT   BINDING         79..81
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /ligand_note="ligand shared between dimeric partners"
FT                   /note="in other chain"
FT                   /evidence="ECO:0000269|PubMed:17496144"
FT   BINDING         92
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /ligand_note="ligand shared between dimeric partners"
FT                   /evidence="ECO:0000269|PubMed:17496144"
FT   BINDING         133
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /ligand_note="ligand shared between dimeric partners"
FT                   /note="in other chain"
FT                   /evidence="ECO:0000269|PubMed:17496144"
FT   BINDING         155..158
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /ligand_note="ligand shared between dimeric partners"
FT                   /note="in other chain"
FT                   /evidence="ECO:0000269|PubMed:17496144"
FT   VARIANT         23
FT                   /note="T -> I (in dbSNP:rs11557236)"
FT                   /id="VAR_030689"
FT   VARIANT         252
FT                   /note="P -> L (in dbSNP:rs3747582)"
FT                   /id="VAR_030690"
FT   MUTAGEN         37
FT                   /note="R->A: Impairs binding to NADPH; abolishes the
FT                   ability to dimerize; enhances binding to ASS1; reduces
FT                   perinuclear localization."
FT                   /evidence="ECO:0000269|PubMed:19254724"
FT   MUTAGEN         41
FT                   /note="K->S: Does not impair binding to NADPH; maintains
FT                   the dimerization properties as the wild type; does not
FT                   affect binding to ASS1; does not affect perinuclear
FT                   localization."
FT                   /evidence="ECO:0000269|PubMed:19254724"
FT   MUTAGEN         81
FT                   /note="Y->A: Impairs binding to NADPH; abolishes the
FT                   ability to dimerize; enhances binding to ASS1; reduces
FT                   perinuclear localization."
FT                   /evidence="ECO:0000269|PubMed:19254724"
FT   MUTAGEN         133
FT                   /note="K->A: Impairs binding to NADPH; enhances binding to
FT                   ASS1; reduces perinuclear localization."
FT                   /evidence="ECO:0000269|PubMed:19254724"
FT   STRAND          6..10
FT                   /evidence="ECO:0007829|PDB:2WM3"
FT   TURN            11..13
FT                   /evidence="ECO:0007829|PDB:2WM3"
FT   HELIX           15..27
FT                   /evidence="ECO:0007829|PDB:2WM3"
FT   STRAND          29..37
FT                   /evidence="ECO:0007829|PDB:2WM3"
FT   HELIX           42..49
FT                   /evidence="ECO:0007829|PDB:2WM3"
FT   STRAND          53..56
FT                   /evidence="ECO:0007829|PDB:2WM3"
FT   HELIX           62..69
FT                   /evidence="ECO:0007829|PDB:2WM3"
FT   STRAND          73..77
FT                   /evidence="ECO:0007829|PDB:2WM3"
FT   HELIX           81..83
FT                   /evidence="ECO:0007829|PDB:2WM3"
FT   HELIX           87..104
FT                   /evidence="ECO:0007829|PDB:2WM3"
FT   STRAND          107..111
FT                   /evidence="ECO:0007829|PDB:2WM3"
FT   HELIX           117..120
FT                   /evidence="ECO:0007829|PDB:2WM3"
FT   TURN            121..123
FT                   /evidence="ECO:0007829|PDB:2WM3"
FT   HELIX           128..143
FT                   /evidence="ECO:0007829|PDB:2WM3"
FT   STRAND          147..151
FT                   /evidence="ECO:0007829|PDB:2WM3"
FT   HELIX           156..160
FT                   /evidence="ECO:0007829|PDB:2WM3"
FT   TURN            161..163
FT                   /evidence="ECO:0007829|PDB:2WM3"
FT   STRAND          171..176
FT                   /evidence="ECO:0007829|PDB:2WM3"
FT   STRAND          185..188
FT                   /evidence="ECO:0007829|PDB:2WM3"
FT   HELIX           190..192
FT                   /evidence="ECO:0007829|PDB:2WM3"
FT   HELIX           193..202
FT                   /evidence="ECO:0007829|PDB:2WM3"
FT   HELIX           204..207
FT                   /evidence="ECO:0007829|PDB:2WM3"
FT   STRAND          211..213
FT                   /evidence="ECO:0007829|PDB:2WM3"
FT   STRAND          216..219
FT                   /evidence="ECO:0007829|PDB:2WM3"
FT   HELIX           221..232
FT                   /evidence="ECO:0007829|PDB:2WM3"
FT   STRAND          236..238
FT                   /evidence="ECO:0007829|PDB:2WM3"
FT   HELIX           244..247
FT                   /evidence="ECO:0007829|PDB:2WM3"
FT   HELIX           254..264
FT                   /evidence="ECO:0007829|PDB:2WM3"
FT   HELIX           272..278
FT                   /evidence="ECO:0007829|PDB:2WM3"
FT   HELIX           285..292
FT                   /evidence="ECO:0007829|PDB:2WM3"
FT   HELIX           293..295
FT                   /evidence="ECO:0007829|PDB:2WM3"
SQ   SEQUENCE   299 AA;  33344 MW;  D740334F8F8D4E1E CRC64;
     MVDKKLVVVF GGTGAQGGSV ARTLLEDGTF KVRVVTRNPR KKAAKELRLQ GAEVVQGDQD
     DQVIMELALN GAYATFIVTN YWESCSQEQE VKQGKLLADL ARRLGLHYVV YSGLENIKKL
     TAGRLAAAHF DGKGEVEEYF RDIGVPMTSV RLPCYFENLL SHFLPQKAPD GKSYLLSLPT
     GDVPMDGMSV SDLGPVVLSL LKMPEKYVGQ NIGLSTCRHT AEEYAALLTK HTRKVVHDAK
     MTPEDYEKLG FPGARDLANM FRFYALRPDR DIELTLRLNP KALTLDQWLE QHKGDFNLL
//
